Insights into Peloton's Financial Performance and Strategic Adjustments
Drug distributors, including rival Cencora, have been benefiting from growing sales of specialty medicines at a time when prices of generic, or copycat, versions have been falling due to intense competition. Cardinal now expects 2024 adjusted earnings in the range of $7.30 to $7.40 per share, compared with $7.20 to $7.35 per share forecast previously. According to LSEG data, analysts were expecting an annual profit of $7.28 per share.
Key Financial Highlights and Strategic Developments in Rare Disease Therapeutics